Bicocca Open Archive

Logo unimib boa
CIARDULLO, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.245
EU - Europa 2.671
AS - Asia 2.371
SA - Sud America 193
AF - Africa 64
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.563
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.167
SG - Singapore 851
IT - Italia 691
HK - Hong Kong 665
RU - Federazione Russa 589
DE - Germania 418
CN - Cina 381
SE - Svezia 271
IE - Irlanda 260
BR - Brasile 166
GB - Regno Unito 123
VN - Vietnam 101
KR - Corea 77
CA - Canada 64
ID - Indonesia 63
NL - Olanda 62
IN - India 61
FI - Finlandia 48
FR - Francia 46
UA - Ucraina 29
JP - Giappone 28
AT - Austria 26
TR - Turchia 26
AU - Australia 18
EG - Egitto 18
BE - Belgio 17
IQ - Iraq 17
PK - Pakistan 16
ZA - Sudafrica 15
DK - Danimarca 14
PL - Polonia 14
IR - Iran 13
BD - Bangladesh 10
ES - Italia 10
MX - Messico 10
RO - Romania 10
SA - Arabia Saudita 10
AR - Argentina 9
PT - Portogallo 9
DZ - Algeria 8
BG - Bulgaria 7
CZ - Repubblica Ceca 7
EC - Ecuador 7
MA - Marocco 6
NG - Nigeria 6
TW - Taiwan 6
CO - Colombia 5
JO - Giordania 5
PH - Filippine 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
IL - Israele 4
TH - Thailandia 4
BY - Bielorussia 3
CH - Svizzera 3
KG - Kirghizistan 3
NO - Norvegia 3
NP - Nepal 3
AL - Albania 2
CY - Cipro 2
GR - Grecia 2
KE - Kenya 2
KZ - Kazakistan 2
LT - Lituania 2
MY - Malesia 2
PA - Panama 2
VE - Venezuela 2
ZM - Zambia 2
ZW - Zimbabwe 2
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
HN - Honduras 1
JE - Jersey 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
PE - Perù 1
PS - Palestinian Territory 1
PY - Paraguay 1
SN - Senegal 1
TJ - Tagikistan 1
TN - Tunisia 1
UY - Uruguay 1
Totale 8.563
Salva come PNG Salva come JPEG
Città #
Ann Arbor 702
Hong Kong 650
Singapore 527
Santa Clara 285
Frankfurt am Main 267
Dublin 251
Chandler 201
Milan 194
Fairfield 175
New York 141
Ashburn 114
Wilmington 99
Princeton 96
Hefei 94
Chicago 92
Seattle 73
Woodbridge 70
Cambridge 67
Jakarta 61
Seoul 61
Houston 60
Altamura 58
London 55
Beijing 53
Moscow 51
Munich 50
Lawrence 47
Shanghai 42
San Diego 36
Rome 34
Los Angeles 33
Boardman 28
Helsinki 28
Bari 25
Dong Ket 24
Monza 22
Nuremberg 22
Ho Chi Minh City 21
Kent 19
São Paulo 19
Toronto 19
Nanjing 18
Brussels 15
Kocaeli 15
Guangzhou 14
Vienna 13
Hanoi 12
Carate Brianza 11
Dearborn 11
Andover 10
Lappeenranta 10
Naples 10
Pune 10
Sydney 10
Turku 10
Brooklyn 9
Capurso 9
Groningen 9
Norwalk 9
Sacramento 9
Florence 8
Hyderabad 8
Linköping 8
Quận Bình Thạnh 8
Riyadh 8
Amsterdam 7
Cairo 7
Cinisello Balsamo 7
New Delhi 7
San Francisco 7
Tokyo 7
Bexley 6
Changsha 6
Columbus 6
Düsseldorf 6
Esslingen am Neckar 6
Hangzhou 6
Raleigh 6
Wenzhou 6
Wroclaw 6
Amman 5
Bergamo 5
Brno 5
Council Bluffs 5
Dallas 5
Erbil 5
Falls Church 5
Floridia 5
Jacksonville 5
Lahore 5
Laurel 5
Lisbon 5
Manila 5
Mexico City 5
Montreal 5
Palermo 5
Paris 5
Quito 5
San Mateo 5
Tashkent 5
Totale 5.416
Salva come PNG Salva come JPEG
Nome #
Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk? 369
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction 343
Exploring the landscape of steatotic liver disease in the general US population 276
Endocrinology and Metabolic Diseases (Including Diabetes) 206
Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy 195
Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study 187
Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 Diabetes 184
Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes 176
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes 162
Seasonal variation in estimated cardiovascular risk in patients with type 2 diabetes 146
Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD 138
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications 138
Lack of awareness of liver organ damage in patients with type 2 diabetes 138
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 115
Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population 114
Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population 114
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 111
Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016 110
Baseline TSH levels and short-term weight loss after different procedures of bariatric surgery 109
Metabolic and psychological features are associated with weight loss 12 months after sleeve gastrectomy 108
An unexpected bilateral mass after total thyroidectomy 106
Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study 106
Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence 105
Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories 104
Risk stratification tools for heart failure in the diabetes clinic 104
Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines 104
Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017–2018 National Health and Nutrition Examination Survey 103
Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. women 103
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes 102
Impact of the duration of type 2 diabetes on the screening for nonal- coholic fatty liver disease and advanced fibrosis 101
Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease 100
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population 99
Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort 98
Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy 97
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions 94
Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population 93
Time trends in liver-related mortality in people with and without diabetes: Results from a population based study 92
Diabetes mellitus is associated with higher serum neurofilament light chain levels in the general U.S. population 91
Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological study 91
Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study 90
Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients 89
Reply to "Liver fibrosis assessed by transient elastography and albuminuria" 89
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 88
Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease 88
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 87
Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting 86
Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes 85
NAFLD and liver fibrosis are not associated with reduced femoral bone mineral density in the general US population 85
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents 85
Comment on “An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD” 84
Reply [to: Use of FibroScan–AST Score to Stratify High-Risk Nonalcoholic Steatohepatitis in US...] 83
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment 81
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes 81
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population 80
Sex-related association of NAFLD and liver fibrosis with body fat distribution in the general US population 80
NAIF: A novel artificial intelligence-based tool for accurate diagnosis of stage F3/F4 liver fibrosis in the general adult population, validated with three external datasets 78
Glycated albumin is associated with all-cause and cardiovascular mortality among U.S. adults with and without diabetes: A retrospective cohort study 77
Non-invasive scores of liver fibrosis in morbidly obese patients 77
Global multi-stakeholder endorsement of the MAFLD definition 77
Development of a new model of insulin sensitivity in patients with type 2 diabetes and association with mortality 75
Differential Association of Sex Hormones with Metabolic Parameters and Body Composition in Men and Women from the United States 72
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes and association with micro- and macrovascular complications 72
Control of Blood Glucose and Cardiovascular Risk Profile 72
Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition 70
Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis 70
Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus 68
The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes 67
Authors' reply to Zou et al 67
Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis 65
Twenty-year trends in heart failure among U.S. adults, 1999–2018: The growing impact of obesity and diabetes 65
Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis 65
Serum neurofilament light chain levels are associated with all-cause mortality in the general US population 65
Steatotic Liver Disease Phenotypes in the United States: The Impact of Alcohol Consumption Assessment 63
Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD 63
Low 25 (OH) vitamin D levels are associated with increased prevalence of NAFLD and significant liver fibrosis 61
Authors' reply to Shang et al. 61
Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States 61
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes 57
Resmetirom for the treatment of nonalcoholic steatohepatitis: Evaluating the robustness of available evidence 57
Advances in fibrosis biomarkers in nonalcoholic fatty liver disease 56
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting 53
Liver stiffness is associated with all-cause mortality in patients with NAFLD: A systematic review and meta-analysis 53
The MAFLD‐MASLD debate: Does cardiovascular risk prediction define the winner? 52
Trends in prevalence of probable fibrotic nonalcoholic steatohepatitis in the United States, 1999-2016 50
Soluble α-Klotho levels, glycemic control and renal function in US adults with type 2 diabetes 50
Silent threats: how NAFLD and hypertension team up in young adults, and the role of sex 45
Prevalence of Noninvasively Detected Clinically Significant Portal Hypertension Among U.S. Adults With and Without Diabetes 41
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes 39
Preferences, Expectations and Attitudes on Basal Insulin from Patient–Physician–Payer Perspective: A Multi-stakeholder Survey by the Italian Diabetes Society (ITA4P Study) 36
Authors' response to Guo, Wei et al. 36
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 34
Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs 26
Evaluating the Prognostic Value of the Triglyceride–Glucose Index in Different Populations: A Critical Analysis 22
Totale 8.911
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.436
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.436
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021998 16 30 45 65 72 70 85 116 133 144 88 134
2021/2022741 117 88 99 42 25 52 28 35 50 62 44 99
2022/20231.240 146 226 123 108 92 228 40 71 87 26 58 35
2023/20241.236 89 42 84 102 112 216 166 53 91 53 34 194
2024/20254.090 215 404 309 233 331 220 288 121 343 517 427 682
2025/2026355 355 0 0 0 0 0 0 0 0 0 0 0
Totale 8.911